US 10538513
Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
granted A61KA61K31/416A61P
Quick answer
US patent 10538513 (Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/416, A61P, A61P1/00, A61P17/00